POZEN Trading Up 4.9% on Earnings Beat (POZN)
POZEN (NASDAQ:POZN)’s share price was up 4.9% during trading on Thursday following a better than expected earnings announcement, ARN reports. The stock traded as high as $9.15 and last traded at $8.56, with a volume of 693,946 shares traded. The stock had previously closed at $8.16.
The company reported $0.09 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.04) by $0.13. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $5.50 million. During the same quarter last year, the company posted ($0.19) earnings per share. POZEN’s revenue was up 433.5% compared to the same quarter last year.
POZN has been the subject of a number of recent research reports. Analysts at TheStreet downgraded shares of POZEN from a “hold” rating to a “sell” rating in a research note on Sunday, March 16th. Finally, analysts at Zacks reiterated an “outperform” rating on shares of POZEN in a research note on Wednesday, March 5th. They now have a $11.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $9.92.
In other POZEN news, Insider John Fort unloaded 13,725 shares of the company’s stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $9.61, for a total value of $131,897.25. Following the completion of the sale, the insider now directly owns 45,005 shares in the company, valued at approximately $432,498. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
The stock’s 50-day moving average is $8.42 and its 200-day moving average is $7.99. The company’s market cap is $251.9 million.
POZEN Inc (NASDAQ:POZN), is a pharmaceutical company focused on transforming medicine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.